BiotechTube

50 mg S-777469 + 200 mg S-777469 + 800 mg S-777469 + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Jul 1, 2007 → Sep 1, 2008

NCT ID
NCT00697710

About 50 mg S-777469 + 200 mg S-777469 + 800 mg S-777469 + Placebo

50 mg S-777469 + 200 mg S-777469 + 800 mg S-777469 + Placebo is a phase 1/2 stage product being developed by Shionogi for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00697710. Target conditions include Atopic Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Dermatitis were approved

Approved (20) Terminated (1) Active (0)
✅LebrikizumabEli LillyApproved
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved
✅Protopic + Corticosteroid + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00697710Phase 1/2Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyApproved
50
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35